2026. Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s727. DOI:https://doi.org/10.25251/evafb145.